🇺🇸 FDA
Patent

US 9180122

5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain

granted A61KA61K31/4412A61K31/444

Quick answer

US patent 9180122 (5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain) held by Takeda Pharmaceutical Company Limited expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/4412, A61K31/444, A61K31/497, A61K45/06